Search results
Results from the WOW.Com Content Network
Cortese said about 5% to 7% of children and 2.5% of adults worldwide have ADHD, which stems from underdeveloped or impaired executive function and self-regulation skills, according to Harvard ...
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...
Alternative treatments to a stimulant medication range from natural products to psychotherapeutic techniques and highly technological interventions. It has been argued that although texts that promote alternative therapies do not directly accuse parents of inadequacy, the claims that the disability is caused by certain factors, such as poor ...
Males with ADHD, children, and adults exhibit higher rates of externalizing disorders or behaviors that manifest as aggressive, disruptive, rule-breaking behaviors, making them more likely to be referred for ADHD treatment. Adult males with ADHD are also more likely to display antisocial behaviors associated with antisocial personality disorder ...
It addresses topics including: diagnosing ADHD in children and adults, attention-deficit hyperactivity disorder management and treatments including medication and/or alternative therapies, parenting children with ADHD, learning disabilities and school challenges, and living with adult ADHD. ADDitude magazine is described by child ...
Viloxazine is indicated to treat attention deficit hyperactivity disorder (ADHD) in children age 6 to 12 years, adolescents age 13 to 17 years, and adults. [1]Analyses of clinical trial data suggest that viloxazine produces moderate reductions in symptoms; it is about as effective as atomoxetine and methylphenidate but with fewer side effects.
Reboxetine, sold under the brand name Edronax among others, is a selective norepinephrine reuptake inhibitor (sNRI) medication marketed as an antidepressant by Pfizer for use in the treatment of major depressive disorder, although it has also been used off-label for panic disorder and attention deficit hyperactivity disorder (ADHD). [4]
By learning to identify tics, adults can refrain from asking or expecting a child to stop ticcing, [23] [24] because "tic suppression can be exhausting, unpleasant, and attention-demanding and can result in a subsequent rebound bout of tics". [24] The presence of ADHD is associated with functional impairment, disruptive behavior, and tic ...